Trovagene (TROV) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Trovagene Announces First Quarter 2016 Financial Results
May 10, 2016 4:06 PM EDTSAN DIEGO, May 10, 2016 /PRNewswire/ --Â Trovagene, Inc. (NASDAQ:Â TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2016.
"I'm thrilled to join Trovagene to drive the development and commercialization of the Company's differentiated molecular diagnostic platform, and to improve the care of cancer patients," said Bill Welch, chief executive officer of Trovagene. "Liquid biopsy for cancer monitoring offers tremendous potential, and our strong balance sheet positions us to execute on our business plan and create... More
